Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. / Levi, Laura I.; Sharma, Shweta; Schleiss, Mark R.; Furrer, Hansjakob; Nixon, Daniel E.; Blackstad, Mark; Hernandez-Alvarado, Nelmary; Dwyer, Dominic E.; Borges, Alvaro H.; Lane, H. Clifford; Lundgren, Jens; Neaton, James D.; Molina, Jean Michel.
In: AIDS, Vol. 36, No. 9, 2022, p. 1265-1272.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy
AU - Levi, Laura I.
AU - Sharma, Shweta
AU - Schleiss, Mark R.
AU - Furrer, Hansjakob
AU - Nixon, Daniel E.
AU - Blackstad, Mark
AU - Hernandez-Alvarado, Nelmary
AU - Dwyer, Dominic E.
AU - Borges, Alvaro H.
AU - Lane, H. Clifford
AU - Lundgren, Jens
AU - Neaton, James D.
AU - Molina, Jean Michel
N1 - Funding Information: This CMV project was funded via Subcontract 13XS134 under Leidos Biomed's Prime Contract HHSN261200800001E and HHSN261201500003I, NCI/NIAID. Funding for the respective trials is noted in the primary publications; see N Engl J Med 2015; 373 : 795–807 for the complete list of START investigators; N Engl J Med 2006; 355 : 2283–96 for the complete list of SMART investigators; and Lancet 2006; 368 : 2125–35 for the complete list of FIRST investigators. Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Objective: The aim of this study was to assess the prevalence of cytomegalovirus (CMV) viremia in HIV-positive patients starting antiretroviral therapy (ART) and to evaluate its impact on clinical outcomes. Design: A retrospective analysis of four clinical trials (INSIGHT FIRST, SMART, START, and ANRS REFLATE TB). Methods: Stored plasma samples from participants were used to measure CMV viremia at baseline prior to initiating ART and at visits through 1 year of follow-up after ART initiation. CMV viremia was measured centrally using a quantitative PCR assay. Within FIRST, associations of CMV viremia at baseline and through 8 months of ART were examined with a composite clinical outcome of AIDS, serious non-AIDS events, or death using Cox proportional hazards regression. Results: Samples from a total of 3176 participants, 1169 from FIRST, 137 from ANRS REFLATE TB, 54 from SMART, and 1816 from START were available with baseline CMV viremia prevalence of 17, 26, 0, and 1%, respectively. Pooled across trials, baseline CMV viremia was associated with low CD4+T-cell counts and high HIV RNA levels. In FIRST, CMV viremia was detected in only 5% of participants between baseline and month 8. After adjustment for CD4+T-cell count and HIV RNA levels, hazard ratios for risk of clinical outcomes was 1.15 (0.86-1.54) and 2.58 (1.68-3.98) in FIRST participants with baseline and follow-up CMV viremia, respectively. Conclusion: Baseline CMV viremia in HIV-positive patients starting ART is associated with advanced infection and only persistent CMV viremia after ART initiation is associated with a higher risk of morbidity and mortality.
AB - Objective: The aim of this study was to assess the prevalence of cytomegalovirus (CMV) viremia in HIV-positive patients starting antiretroviral therapy (ART) and to evaluate its impact on clinical outcomes. Design: A retrospective analysis of four clinical trials (INSIGHT FIRST, SMART, START, and ANRS REFLATE TB). Methods: Stored plasma samples from participants were used to measure CMV viremia at baseline prior to initiating ART and at visits through 1 year of follow-up after ART initiation. CMV viremia was measured centrally using a quantitative PCR assay. Within FIRST, associations of CMV viremia at baseline and through 8 months of ART were examined with a composite clinical outcome of AIDS, serious non-AIDS events, or death using Cox proportional hazards regression. Results: Samples from a total of 3176 participants, 1169 from FIRST, 137 from ANRS REFLATE TB, 54 from SMART, and 1816 from START were available with baseline CMV viremia prevalence of 17, 26, 0, and 1%, respectively. Pooled across trials, baseline CMV viremia was associated with low CD4+T-cell counts and high HIV RNA levels. In FIRST, CMV viremia was detected in only 5% of participants between baseline and month 8. After adjustment for CD4+T-cell count and HIV RNA levels, hazard ratios for risk of clinical outcomes was 1.15 (0.86-1.54) and 2.58 (1.68-3.98) in FIRST participants with baseline and follow-up CMV viremia, respectively. Conclusion: Baseline CMV viremia in HIV-positive patients starting ART is associated with advanced infection and only persistent CMV viremia after ART initiation is associated with a higher risk of morbidity and mortality.
KW - AIDS
KW - antiretroviral therapy
KW - CD4T-cell count
KW - cytomegalovirus
KW - HIV
KW - mortality
U2 - 10.1097/QAD.0000000000003238
DO - 10.1097/QAD.0000000000003238
M3 - Journal article
C2 - 35442221
AN - SCOPUS:85134428246
VL - 36
SP - 1265
EP - 1272
JO - AIDS
JF - AIDS
SN - 1350-2840
IS - 9
ER -
ID: 345056375